TUBB3 and colorectal cancer: 69 cases (15.5%) were weakly positive, 149 cases (33.5%) were moderately positive, and 188 cases (42.2%) were strongly positive.[64] Other studies have shown that some miRNAs, such as miR-200b-3p, can regulate the resistance of colorectal cancer cells to oxaliplatin by targeting TUBB3.